title: Confounding of the Comparative Safety of Prenatal Opioid Agonist Therapy.
abstract: Prenatal opioid agonist therapy with methadone or buprenorphine prevents maternal illicit opioid use and withdrawal and improves pregnancy outcomes compared to heroin use alone. Historically, methadone has been the first-line opioid agonist therapy for pregnant opioid dependent women; in recent years buprenorphine has become first-line treatment for some opioid dependent pregnant women. While there is some evidence of better outcomes in neonates exposed to buprenorphine vs. methadone, the effect of confounding from differences in women who use buprenorphine and methadone has not been carefully examined in most studies. This review explores mechanisms by which confounding can arise in measuring associations between prenatal buprenorphine vs. methadone exposure on neonatal outcomes using a graphical approach, directed acyclic graphs. The goal of this paper is to facilitate better understanding of the factors influencing neonatal abstinence syndrome and accurate assessment of the comparative safety of opioid agonist therapies on the neonate.
authors.affiliation: Departments of Surgery and of Medicine, Queen's University, Canada.
authors.forename: Susan B
authors.initials: SB
authors.lastname: Brogly
authors.affiliation: Department of Epidemiology, Boston University School of Public Health, USA.
authors.forename: Kristen A
authors.initials: KA
authors.lastname: Hahn
authors.affiliation: Department of Epidemiology, Harvard School of Public Health, USA.
authors.forename: Sonia Hernandez
authors.initials: SH
authors.lastname: Diaz
authors.affiliation: Department of Epidemiology, Boston University School of Public Health, USA.
authors.forename: Martha
authors.initials: M
authors.lastname: Werler
keywords: Buprenorphine; Confounding; Methadone; Neonatal abstinence syndrome; Pregnancy